The development of a CMV vaccine has been 50 years in the making.

Novosteo has developed a targeted drug combination to help accelerate the repair of bone fractures.

Novel compounds could be effective in treating brain-eating amoeba.

As the industry's reliance on CDMOs increases, how can the sector adapt to meet companies' needs?

How can manufacturing be improved for viral vectors?

Sitting Down With… Mike McMullen, President and CEO, Agilent Technologies, Santa Clara, California, USA.

Digital technologies are here – but are they being used adequately?

Looking to set up your own company but lacking a sense of business acumen? There may be help at hand.

How can we ensure we are better prepared to develop new vaccines and treatments for future infectious disease outbreaks?

Sitting Down With… Tom Moody, VP of Technology Development and Commercialization at Almac, Craigavon, UK.